Fennec Pharmaceuticals Inc
NASDAQ:FENC
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
F
|
Fennec Pharmaceuticals Inc
NASDAQ:FENC
|
US |
|
Bank of China Ltd
SSE:601988
|
CN |
|
Allis Electric Co Ltd
TWSE:1514
|
TW |
|
T
|
Tamar Petroleum Ltd
TASE:TMRP
|
IL |
|
Woodward Inc
NASDAQ:WWD
|
US |
Fennec Pharmaceuticals Inc
Fennec Pharmaceuticals, Inc. operates as a biopharmaceutical company. The company is headquartered in Durham, North Carolina and currently employs 10 full-time employees. The company went IPO on 2001-06-05. The firm is focused on the development of PEDMARK for the prevention of platinum-induced ototoxicity in pediatric cancer patients. The Company’s only product candidate in the clinical-stage of development is PEDMARK. The company announced two results of Phase III clinical trials for the prevention of cisplatin induced hearing loss, or ototoxicity in children, including the pivotal Phase III study SIOPEL 6 and the proof-of-concept Phase III study in collaboration with the Children’s Oncology Group (COG ACCL0431). PEDMARK has the potential to reduce the incidence and/or grade of chemotherapy-induced hearing loss. The Company’s four subsidiaries includes Oxiquant, Inc. and Fennec Pharmaceuticals, Inc., both Delaware corporations, Cadherin Biomedical Inc., a Canadian company, and Fennec Pharmaceuticals (EU) Limited (Fennec Limited), an Ireland company. Apart from Fennec Pharmaceuticals, Inc., all subsidiaries are inactive.
Fennec Pharmaceuticals, Inc. operates as a biopharmaceutical company. The company is headquartered in Durham, North Carolina and currently employs 10 full-time employees. The company went IPO on 2001-06-05. The firm is focused on the development of PEDMARK for the prevention of platinum-induced ototoxicity in pediatric cancer patients. The Company’s only product candidate in the clinical-stage of development is PEDMARK. The company announced two results of Phase III clinical trials for the prevention of cisplatin induced hearing loss, or ototoxicity in children, including the pivotal Phase III study SIOPEL 6 and the proof-of-concept Phase III study in collaboration with the Children’s Oncology Group (COG ACCL0431). PEDMARK has the potential to reduce the incidence and/or grade of chemotherapy-induced hearing loss. The Company’s four subsidiaries includes Oxiquant, Inc. and Fennec Pharmaceuticals, Inc., both Delaware corporations, Cadherin Biomedical Inc., a Canadian company, and Fennec Pharmaceuticals (EU) Limited (Fennec Limited), an Ireland company. Apart from Fennec Pharmaceuticals, Inc., all subsidiaries are inactive.
Sales: Net product sales were $13.8 million in Q4 2025 and $44.6 million for FY2025, up ~75% and ~50% versus the comparable 2024 periods.
Growth drivers: Management attributes growth to more treated patients, conversion improvements through the Fennec HEARS program and a targeted expansion of the field sales force focused on AYA patients.
Commercial push: Company expanded territory managers and expects those hires to ramp through 2026 with a material contribution by H2 2026.
Medical evidence: Multiple investigator-initiated studies and new real-world data (including a multi-institutional retrospective in adult head & neck cancer) are underway to support broader use beyond pediatrics.
Japan & Europe: An investigator-led PEDMARK study in Japan is progressing; Norgine launched PEDMARQSI in the U.K. and Germany in 2025 and plans 8–10 country launches in 2026.
Balance sheet & cash: Cash and cash equivalents were $36.8 million at 12/31/2025 after net equity proceeds of ~$42 million and a $21.8 million debt paydown; company now reports zero debt and expects positive cash flow in Q1 2026.
Patent settlement: Settlement with Cipla delays generic entry until September 1, 2033 (or earlier under select conditions), which management says preserves exclusivity and reduces future G&A spend.
2026 spend outlook: Cash operating expenses expected to rise from ~ $35 million in 2025 to ~ $50 million in 2026 to support commercial and medical expansion.
